仅获得一或两个囊胚时 PGT-A 的价值:倾向性评分匹配与成本效果研究
该研究纳入2013年4月至2022年7月间1829例仅获一或两个囊胚的患者,经倾向性评分1:1匹配后每组242例,比较 IVF 联合或不联合 PGT-A 的效果与费用。结果显示 PGT-A 组每患者累积活产率与对照组相似,但每移植活产率更高、流产率更低,且从取卵到周期结束时间更短;ICER 随母亲年龄增加而降低。
要点
- 仅获一或两个囊胚时,PGT-A 组与对照组的每患者累积活产率相似(27.3% vs 23.6%)。
- PGT-A 组每移植活产率更高(41.5% vs 16.2%),每临床妊娠流产率更低(13.9% vs 30.1%)。
- PGT-A 组取卵至周期结束时间更短(74天 vs 131天,P<0.001)。
核心结论
- 在专家 IVF 诊所对具备指征的患者实施时,即使仅获得一或两个囊胚,PGT-A 仍具有临床价值。
- PGT-A 减少了移植次数和流产,每患者累积活产率未受影响,并可在更短时间内达到这些结局。
- PGT-A 相对于非 PGT-A 的 ICER 随母亲年龄增加而降低。
研究设计与样本
- 研究纳入2013年4月至2022年7月间1829例仅获得一或两个囊胚的患者,其中非 PGT-A 组368例、PGT-A 组1461例。
- 按母亲年龄、受精的减数第二次分裂中期卵母细胞数和获囊胚数进行1:1倾向性评分匹配,每组各242例。
- 比较非 PGT-A 组与 PGT-A 组的每移植活产率、每患者累积活产率、每临床妊娠流产率、取卵至 IVF 周期结束天数(主要结局)、诊所平均费用和增量成本效果比(ICER)。
主要发现
- 非 PGT-A 组实施的移植次数是 PGT-A 组的两倍以上,但每患者累积活产率两组相似:非 PGT-A 组23.6%(95%CI 18.5-29.5%)vs PGT-A 组27.3%(95%CI 21.9-33.4%)。
- 每移植活产率 PGT-A 组高于非 PGT-A 组:41.5%(95%CI 33.9-49.4%)vs 16.2%(95%CI 12.6-20.5%)。
- 每临床妊娠流产率 PGT-A 组低于非 PGT-A 组:13.9%(95%CI 7.5-24.0%)vs 30.1%(95%CI 21.8-42.6%);每患者流产率 PGT-A 组也低于非 PGT-A 组:4.5%(95%CI 2.4-8.2%)vs 9.5%(95%CI 6.2-14.1%)。
- 取卵至 IVF 周期结束平均天数 PGT-A 组短于非 PGT-A 组:74天(95%CI 61-87)vs 131天(95%CI 113-150),P<0.001,检验效能=99.8%。
- PGT-A 为节省取卵至周期结束时间的 ICER 总体为499欧元,根据获囊胚数和/或母亲年龄在170欧元至2065欧元之间;为避免流产的 ICER 为18968欧元,在年龄≥35岁且获两个囊胚的患者中降至3525欧元。
临床怎么用
- 作者认为,在专家 IVF 诊所对具备指征的患者,即使仅获得一或两个囊胚,PGT-A 仍具有临床价值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the effectiveness and cost of in-vitro fertilization (IVF) with or without preimplantation genetic testing for aneuploidy (PGT-A) when only one or two blastocysts are obtained. METHODS: A dataset was gathered from 1829 patients including 368 non-PGT-A and 1461 PGT-A cycles with one or two blastocysts obtained, between April 2013 and July 2022. Patients were matched 1:1 by propensity-score matching for maternal age, number of metaphase-II oocytes inseminated and number of blastocysts obtained, achieving a database of 242 patients per group. The non-PGT-A and PGT-A groups were compared for differences in live birth rate (LBR) per embryo transfer (ET), cumulative LBR per patient, miscarriage rate (MR) per clinical pregnancy, number of days between oocyte retrieval and conclusion of the IVF cycle (primary outcome), mean expenses incurred at the clinic and incremental cost-effectiveness ratio (ICER). RESULTS: More than twice as many ETs were conducted in the non-PGT-A group compared with the PGT-A group, yet the cumulative LBR per patient was similar between groups (23.6% (95% CI, 18.5-29.5%) vs 27.3% (95% CI, 21.9-33.4%)). This outcome was achieved with a higher LBR per ET (16.2% (95% CI, 12.6-20.5%) vs 41.5% (95% CI, 33.9-49.4%)) and lower MR per clinical pregnancy (30.1% (95% CI, 21.8-42.6%) vs 13.9% (95% CI, 7.5-24.0%)) in the PGT-A group. The MR per patient was also lower in the PGT-A group (9.5% (95% CI, 6.2-14.1%) vs 4.5% (95% CI, 2.4-8.2%)). The mean duration between oocyte retrieval and IVF cycle conclusion was 131 (95% CI, 113-150) days in the non-PGT-A group vs 74 (95% CI, 61-87) days in the PGT-A group (P < 0.001; power = 99.8%). The ICER of PGT-A for the months saved between oocyte retrieval and conclusion of the IVF cycle was €499 overall, ranging between €170 and €2065 according to the number of blastocysts obtained and/or maternal age. The ICER of PGT-A for prevented miscarriages was €18 968, decreasing to €3525 when calculated among patients aged ≥ 35 years with two blastocysts obtained. CONCLUSIONS: When conducted in expert IVF clinics for patients indicated for the procedure, PGT-A is clinically valuable even when only one or two blastocysts are obtained. PGT-A reduces the number of ETs and miscarriages while the cumulative LBR per patient remains unaffected, and allows these outcomes to be achieved in a shorter timeframe. The ICER of PGT-A vs non PGT-A decreased as maternal age increased. © 2024 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Cimadomo D, Taggi M, Cimadomo V, et al. Value of PGT-A when only one or two blastocysts are obtained: propensity-score matching and cost-effectiveness study. Ultrasound Obstet Gynecol. 2024. PMID: 39644516. doi:10.1002/uog.29148
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。